Last reviewed · How we verify
HBS-201
HBS-201 is a Small molecule drug developed by Harmony Biosciences Management, Inc.. It is currently in Phase 1 development. Also known as: pitolisant delayed-release (DR), pitolisant hydrochloride.
At a glance
| Generic name | HBS-201 |
|---|---|
| Also known as | pitolisant delayed-release (DR), pitolisant hydrochloride |
| Sponsor | Harmony Biosciences Management, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBS-201 CI brief — competitive landscape report
- HBS-201 updates RSS · CI watch RSS
- Harmony Biosciences Management, Inc. portfolio CI
Frequently asked questions about HBS-201
What is HBS-201?
HBS-201 is a Small molecule drug developed by Harmony Biosciences Management, Inc..
Who makes HBS-201?
HBS-201 is developed by Harmony Biosciences Management, Inc. (see full Harmony Biosciences Management, Inc. pipeline at /company/harmony-biosciences-management-inc).
Is HBS-201 also known as anything else?
HBS-201 is also known as pitolisant delayed-release (DR), pitolisant hydrochloride.
What development phase is HBS-201 in?
HBS-201 is in Phase 1.
Related
- Manufacturer: Harmony Biosciences Management, Inc. — full pipeline
- Also known as: pitolisant delayed-release (DR), pitolisant hydrochloride
- Compare: HBS-201 vs similar drugs
- Pricing: HBS-201 cost, discount & access